Login to Your Account

Zaltrap Gets FDA Approval; Commercial Potential Mixed

By Jennifer Boggs
Managing Editor

Monday, August 6, 2012
Regeneron Inc.'s Zaltrap (ziv-aflibercept) won FDA approval Friday in metastatic colorectal cancer, for use in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy, a little more than a year after surprising investors with positive data in a pivotal trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription